Abbott Laboratories stock is trading just below $117 after U.S. regulators cleared a dual glucose-ke

Abbott Laboratories and a proposed class of shareholders have reached an $88.5 million settlement to resolve claims that the company misled investors about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, in a deal that comes a month after an Illinois federal judge tossed the suit.

Abbott Laboratories stock trades with a $670 million legal overhang after a formula settlement and a

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Abbott Laboratories stock is trading close to analysts’ consensus target, backed by strong Q2 diagno

The settlement resolves allegations that the products caused gastrointestinal disease among infants.

In August 2026, Abbott Laboratories agreed to pay approximately US$670 million to resolve the Gill case and around 2,000 additional necrotizing enterocolitis-related claims tied to its preterm infant formulas, without admitting liability and following several favorable court rulings for formula manufacturers. This large settlement trims a single, very large jury award while providing greater clarity on Abbott’s remaining infant-formula litigation exposure and case mix. We’ll now explore how...

These two high-quality dividend payers have had very different fortunes recently.

Legal settlement reshapes the risk picture for Abbott Laboratories stock Abbott Laboratories (ABT) has agreed to resolve the Gill case and about 2,000 related necrotizing enterocolitis claims linked to its preterm infant formulas for roughly US$670 million, reframing investors’ view of its legal overhang. See our latest analysis for Abbott Laboratories. Recent trading shows momentum building in Abbott Laboratories stock, with the share price up 13.18% over 30 days and 33.44% over 90 days,...

Abbott Laboratories stock is trading in the mid-$110s as of August 22, 2026, with fresh Q2 earnings,